BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol 2016;28:208-22. [PMID: 27321574 DOI: 10.1016/j.smim.2016.06.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Sheen JH, Strainic MG, Liu J, Zhang W, Yi Z, Medof ME, Heeger PS. TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement. J Immunol 2017;199:278-91. [PMID: 28539427 DOI: 10.4049/jimmunol.1700339] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
2 Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol 2018;14:26-47. [PMID: 29199277 DOI: 10.1038/nrneph.2017.156] [Cited by in Crossref: 196] [Cited by in F6Publishing: 183] [Article Influence: 39.2] [Reference Citation Analysis]
3 Pérez-Alós L, Bayarri-Olmos R, Skjoedt MO, Garred P. Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade. FASEB J 2019;33:12723-34. [PMID: 31469600 DOI: 10.1096/fj.201901643R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Zheng J, Ren X, Jiang Z, Chen D, Zhao W, Li L. Lectin-induced renal local complement activation is involved in tubular interstitial injury in diabetic nephropathy. Clinica Chimica Acta 2018;482:65-73. [DOI: 10.1016/j.cca.2018.03.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
5 Hawksworth OA, Li XX, Coulthard LG, Wolvetang EJ, Woodruff TM. New concepts on the therapeutic control of complement anaphylatoxin receptors. Mol Immunol 2017;89:36-43. [PMID: 28576324 DOI: 10.1016/j.molimm.2017.05.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
6 Nebbioso M, Lambiase A, Cerini A, Limoli PG, La Cava M, Greco A. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int J Mol Sci 2019;20:E1693. [PMID: 30987401 DOI: 10.3390/ijms20071693] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
7 Shi Y, Chen X, Liu J, Fan X, Jin Y, Gu J, Liang J, Liang X, Wang C. Isoquercetin Improves Inflammatory Response in Rats Following Ischemic Stroke. Front Neurosci 2021;15:555543. [PMID: 33633530 DOI: 10.3389/fnins.2021.555543] [Reference Citation Analysis]
8 Pınarbaşı AS, Dursun I, Gokce I, Çomak E, Saygılı S, Bayram MT, Donmez O, Melek E, Tekcan D, Çiçek N, Yılmaz D, Tabel Y, Yıldırım ZY, Bahat E, Koyun M, Soylu A, Canpolat N, Aksu B, Çelakıl ME, Taşdemir M, Benzer M, Özçelik G, Bakkaloğlu SA, Düşünsel R. Predictors of poor kidney outcome in children with C3 glomerulopathy. Pediatr Nephrol 2021;36:1195-205. [PMID: 33130981 DOI: 10.1007/s00467-020-04799-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
10 Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant 2021:gfab281. [PMID: 34596686 DOI: 10.1093/ndt/gfab281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Druart M, Le Magueresse C. Emerging Roles of Complement in Psychiatric Disorders. Front Psychiatry 2019;10:573. [PMID: 31496960 DOI: 10.3389/fpsyt.2019.00573] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
12 Ali HA, Pavlisko EN, Snyder LD, Frank M, Palmer SM. Complement system in lung transplantation. Clin Transplant 2018;32:e13208. [DOI: 10.1111/ctr.13208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
13 Bosco A, Anderson SR, Breen KT, Romero CO, Steele MR, Chiodo VA, Boye SL, Hauswirth WW, Tomlinson S, Vetter ML. Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma. Mol Ther 2018;26:2379-96. [PMID: 30217731 DOI: 10.1016/j.ymthe.2018.08.017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
14 Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol 2017;38:383-94. [PMID: 28416449 DOI: 10.1016/j.it.2017.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
15 Macpherson A, Liu X, Dedi N, Kennedy J, Carrington B, Durrant O, Heywood S, van den Elsen J, Lawson ADG. The rational design of affinity-attenuated OmCI for the purification of complement C5. J Biol Chem 2018;293:14112-21. [PMID: 30030376 DOI: 10.1074/jbc.RA118.004043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
16 Franzin R, Stasi A, Fiorentino M, Stallone G, Cantaluppi V, Gesualdo L, Castellano G. Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage. Front Immunol 2020;11:734. [PMID: 32457738 DOI: 10.3389/fimmu.2020.00734] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
17 Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 2016;221:1046-57. [PMID: 27353192 DOI: 10.1016/j.imbio.2016.06.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
18 Morigi M, Perico L, Corna D, Locatelli M, Cassis P, Carminati CE, Bolognini S, Zoja C, Remuzzi G, Benigni A, Buelli S. C3a receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight 2020;5:131849. [PMID: 32161193 DOI: 10.1172/jci.insight.131849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
19 Huang Y. Evolution of compstatin family as therapeutic complement inhibitors. Expert Opin Drug Discov 2018;13:435-44. [PMID: 29402126 DOI: 10.1080/17460441.2018.1437139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 Mathern DR, K Horwitz J, Heeger PS. Absence of recipient C3aR1 signaling limits expansion and differentiation of alloreactive CD8+ T cell immunity and prolongs murine cardiac allograft survival. Am J Transplant 2019;19:1628-40. [PMID: 30565852 DOI: 10.1111/ajt.15222] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
21 Verghese DA, Chun N, Paz K, Fribourg M, Woodruff TM, Flynn R, Hu Y, Xiong H, Zhang W, Yi Z, Du J, Blazar BR, Heeger PS. C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. JCI Insight 2018;3:124646. [PMID: 30568034 DOI: 10.1172/jci.insight.124646] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
22 Verhamme IM, Leonard SE, Perkins RC. Proteases: Pivot Points in Functional Proteomics. Methods Mol Biol 2019;1871:313-92. [PMID: 30276748 DOI: 10.1007/978-1-4939-8814-3_20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Iyer A, Xu W, Reid RC, Fairlie DP. Chemical Approaches to Modulating Complement-Mediated Diseases. J Med Chem 2018;61:3253-76. [DOI: 10.1021/acs.jmedchem.7b00882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Riley SP, Fish AI, Del Piero F, Martinez JJ. Immunity against the Obligate Intracellular Bacterial Pathogen Rickettsia australis Requires a Functional Complement System. Infect Immun 2018;86:e00139-18. [PMID: 29581196 DOI: 10.1128/IAI.00139-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Mukai R, Okunuki Y, Husain D, Kim CB, Lambris JD, Connor KM. The Complement System Is Critical in Maintaining Retinal Integrity during Aging. Front Aging Neurosci 2018;10:15. [PMID: 29497373 DOI: 10.3389/fnagi.2018.00015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
26 Lorés-Motta L, Paun CC, Corominas J, Pauper M, Geerlings MJ, Altay L, Schick T, Daha MR, Fauser S, Hoyng CB, den Hollander AI, de Jong EK. Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation: Implications in Age-Related Macular Degeneration. Ophthalmology 2018;125:1064-74. [PMID: 29398083 DOI: 10.1016/j.ophtha.2017.12.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
27 Chinchilla B, Foltopoulou P, Fernandez-Godino R. Tick-over-mediated complement activation is sufficient to cause basal deposit formation in cell-based models of macular degeneration. J Pathol 2021. [PMID: 34155630 DOI: 10.1002/path.5747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Anliker M, Schmidt CQ, Harder MJ, Ganchev G, von Zabern I, Höchsmann B, Schrezenmeier H, Weinstock C. Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay. Transfusion 2018;58:2992-3002. [PMID: 30367826 DOI: 10.1111/trf.14893] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Galindo-Izquierdo M, Pablos Alvarez JL. Complement as a Therapeutic Target in Systemic Autoimmune Diseases. Cells 2021;10:148. [PMID: 33451011 DOI: 10.3390/cells10010148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ricklin D, Lambris JD. Complement therapeutics. Semin Immunol 2016;28:205-7. [PMID: 27522923 DOI: 10.1016/j.smim.2016.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
31 Park DH, Connor KM, Lambris JD. The Challenges and Promise of Complement Therapeutics for Ocular Diseases. Front Immunol 2019;10:1007. [PMID: 31156618 DOI: 10.3389/fimmu.2019.01007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
32 Discipio RG, Schraufstatter IU. Magnetic bead based assays for complement component C5. Journal of Immunological Methods 2017;450:50-7. [DOI: 10.1016/j.jim.2017.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Ma Y, Liu Y, Zhang Z, Yang GY. Significance of Complement System in Ischemic Stroke: A Comprehensive Review. Aging Dis 2019;10:429-62. [PMID: 31011487 DOI: 10.14336/AD.2019.0119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 11.7] [Reference Citation Analysis]
34 Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy., Nastasi. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol 2018;29:283-94. [PMID: 29030465 DOI: 10.1681/ASN.2017030258] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 7.6] [Reference Citation Analysis]
35 Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Mol Immunol 2017;89:10-21. [PMID: 28576323 DOI: 10.1016/j.molimm.2017.05.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
36 Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Front Immunol 2020;11:1460. [PMID: 32793201 DOI: 10.3389/fimmu.2020.01460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Zaal A, Dieker M, Oudenampsen M, Turksma AW, Lissenberg-Thunnissen SN, Wouters D, van Ham SM, Ten Brinke A. Anaphylatoxin C5a Regulates 6-Sulfo-LacNAc Dendritic Cell Function in Human through Crosstalk with Toll-Like Receptor-Induced CREB Signaling. Front Immunol 2017;8:818. [PMID: 28769928 DOI: 10.3389/fimmu.2017.00818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
38 Ispasanie E, Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Front Immunol 2021;12:747594. [PMID: 34691058 DOI: 10.3389/fimmu.2021.747594] [Reference Citation Analysis]
39 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense. Immunol Rev 2016;274:33-58. [PMID: 27782325 DOI: 10.1111/imr.12500] [Cited by in Crossref: 139] [Cited by in F6Publishing: 130] [Article Influence: 27.8] [Reference Citation Analysis]
41 Teçza M, Kagawa TF, Jain M, Cooney JC. Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease. Comput Struct Biotechnol J 2021;19:2356-65. [PMID: 33897974 DOI: 10.1016/j.csbj.2021.04.024] [Reference Citation Analysis]
42 Chen JY, Cortes C, Ferreira VP. Properdin: A multifaceted molecule involved in inflammation and diseases. Mol Immunol 2018;102:58-72. [PMID: 29954621 DOI: 10.1016/j.molimm.2018.05.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
43 Bećarević M. Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals. Curr Rheumatol Rep 2017;19:40. [PMID: 28631067 DOI: 10.1007/s11926-017-0669-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
44 Ermert D, Ram S, Laabei M. The hijackers guide to escaping complement: Lessons learned from pathogens. Mol Immunol 2019;114:49-61. [PMID: 31336249 DOI: 10.1016/j.molimm.2019.07.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
45 Hertz CE, Bayarri-Olmos R, Kirketerp-Møller N, van Putten S, Pilely K, Skjoedt MO, Garred P. Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities. Front Immunol 2018;9:1945. [PMID: 30210498 DOI: 10.3389/fimmu.2018.01945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
46 Gaya da Costa M, Poppelaars F, Berger SP, Daha MR, Seelen MA. The lectin pathway in renal disease: old concept and new insights. Nephrol Dial Transplant 2018;33:2073-9. [PMID: 29701808 DOI: 10.1093/ndt/gfy073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
47 Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 2017;13:538-47. [DOI: 10.1038/nrrheum.2017.125] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 19.0] [Reference Citation Analysis]
48 Pandey MK, Grabowski GA, Köhl J. An unexpected player in Gaucher disease: The multiple roles of complement in disease development. Semin Immunol 2018;37:30-42. [PMID: 29478824 DOI: 10.1016/j.smim.2018.02.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
49 Cai J, Zhao C, Du Y, Huang Y, Zhao Q. Amentoflavone ameliorates cold stress-induced inflammation in lung by suppression of C3/BCR/NF-κB pathways. BMC Immunol 2019;20:49. [PMID: 31888465 DOI: 10.1186/s12865-019-0331-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
50 Zhang L, Qiu W, Crooke S, Li Y, Abid A, Xu B, Finn MG, Lin F. Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo. ACS Chem Biol 2017;12:539-47. [PMID: 28045484 DOI: 10.1021/acschembio.6b00994] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
51 Mishra R, Rana S. A rational search for discovering potential neutraligands of human complement fragment 5a (hC5a). Bioorganic & Medicinal Chemistry 2019;27:115052. [DOI: 10.1016/j.bmc.2019.115052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
52 Zhang L, Fedorov Y, Adams D, Lin F. Identification of complement inhibitory activities of two chemotherapeutic agents using a high-throughput cell imaging-based screening assay. Mol Immunol 2018;101:86-91. [PMID: 29909366 DOI: 10.1016/j.molimm.2018.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Zaal A, van Ham SM, Ten Brinke A. Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2. Immunol Lett 2019;209:45-52. [PMID: 30959077 DOI: 10.1016/j.imlet.2019.03.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
54 Hohenstein B, Amann K, Menne J. Membranoproliferative Glomerulonephritis und C3‑Glomerulopathie. Internist 2019;60:458-67. [DOI: 10.1007/s00108-019-0572-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Rizk DV, Maillard N, Julian BA, Knoppova B, Green TJ, Novak J, Wyatt RJ. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Front Immunol 2019;10:504. [PMID: 30941137 DOI: 10.3389/fimmu.2019.00504] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
56 Trzeciak A, Pietropaoli AP, Kim M. Biomarkers and Associated Immune Mechanisms for Early Detection and Therapeutic Management of Sepsis. Immune Netw 2020;20:e23. [PMID: 32655971 DOI: 10.4110/in.2020.20.e23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
57 Subías Hidalgo M, Yébenes H, Rodríguez-Gallego C, Martín-Ambrosio A, Domínguez M, Tortajada A, Rodríguez de Córdoba S, Llorca O. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. Eur J Immunol 2017;47:504-15. [PMID: 28083930 DOI: 10.1002/eji.201646758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
58 Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. Immunol Rev 2016;274:152-71. [PMID: 27782321 DOI: 10.1111/imr.12475] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 19.8] [Reference Citation Analysis]
59 Giorgio C, Zippoli M, Cocchiaro P, Castelli V, Varrassi G, Aramini A, Allegretti M, Brandolini L, Cesta MC. Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives. Biomedicines 2021;9:399. [PMID: 33917266 DOI: 10.3390/biomedicines9040399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]